December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

12.62 +0.17 (+1.37%)
Streaming Delayed Price Updated: 10:19 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Erasca, Inc. - Common Stock

News headline image
Registration Momentum Builds Across the Oncology Pipeline
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
Erasca Reports First Quarter 2024 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026 
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at Upcoming Investor Conferences in November
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the Cantor Global Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports First Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activity 
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Pricing of Underwritten Offering of Common Stock
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at Upcoming Investor Conferences
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
From Erasca, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.